Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 163

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 163
---
Item 1a. Risk Factors

Summary of Risk Factors

Below is a summary of the
principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that
we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under
the heading “Risk Factors” and should be carefully considered, together with other information in this Form 10-K and our other
filings with the SEC, before making an investment decision regarding our common stock.

    ●
    We will require additional capital to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, if at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates and have substantial doubt about our ability to continue as a going concern.

    ●
    Our ability to successfully engage with, and satisfactorily respond to, requests for information from the FDA in the future.

    ●
    We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future.  We are not currently profitable, and we may never achieve or sustain profitability.

    ●
    We will require additional capital to fund our operations and if we fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates.

    ●
    We are significantly dependent on the success of our DN-TNF product platform and Natural Killer Cell Priming Platform (INKmune), CORDStrom, and our product candidates based on these platforms.

    ●
    We need to attract and retain highly skilled personnel; we may be unable to effectively manage growth with our limited resources.

    ●
    We depend upon our senior management and key consultants and their loss or unavailability could put us at a competitive disadvantage.

    ●
    The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.

    ●
    We can provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinical studies will be favorable.

    ●
    Drug discovery and development is a complex, time-consuming and expensive process with a high rate of failure.

    ●
    We may face legal claims; legal disputes are expensive, and we may not be able to afford the costs.

    ●
    We can